Skip to main content
EOLS
NASDAQ Life Sciences

Evolus Partners with IBSA for Exclusive U.S. Rights to Market-Leading Profhilo® Skin Quality Injectable

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$6.85
Mkt Cap
$457.032M
52W Low
$3.86
52W High
$10.2
52W Position info
77% above low
Off High info
33% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

EOLS sits 77% above its 52-week low of $3.86.

Summary

Evolus entered an exclusive licensing deal with IBSA to bring Profhilo®, a leading European skin quality injectable, to the U.S. market, expanding its aesthetic portfolio.


Key Events · M&A and Partnerships · EOLS

  • Exclusive U.S. Licensing Agreement

    Evolus secured exclusive rights from IBSA to develop and commercialize Profhilo®, a hyaluronic acid product for skin quality, in the United States.

  • Expansion into Skin Quality Market

    This partnership expands Evolus' injectable portfolio into the rapidly growing and underpenetrated skin quality segment, complementing its existing neurotoxin and dermal filler products.

  • Capital-Efficient Deal Structure

    The agreement requires no upfront payments or milestone payments, with economics structured through a transfer-price model designed to support gross margins.

  • Market-Leading Product

    Profhilo® is a market-leading injectable in Europe with over 4.8 million treatments administered globally, providing a strong foundation for U.S. market entry.


Analysis · EOLS · Life Sciences

Evolus has secured exclusive U.S. rights to Profhilo®, a globally recognized and market-leading injectable for skin quality. This strategic partnership expands Evolus' portfolio into a high-growth aesthetic segment with a proven product, positioning the company for long-term revenue diversification and growth without requiring upfront payments.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EOLS was trading at $6.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $457M. The 52-week trading range was $3.86 to $10.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EOLS - Latest Insights

EOLS
Nov 04, 2026, 4:57 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.39
Real-time Price: $6.50 info
Change: -$0.890 (-12%) info
Market Cap: $431.548M info
EOLS
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $7.47
Real-time Price: $6.50 info
Change: -$0.970 (-13%) info
Market Cap: $431.548M info
EOLS
Oct 02, 2026, 10:45 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $7.19
Real-time Price: $6.50 info
Change: -$0.685 (-10%) info
Market Cap: $431.548M info
EOLS
Aug 05, 2026, 4:56 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.53
Real-time Price: $6.50 info
Change: -$0.030 (-0.46%) info
Market Cap: $431.548M info
EOLS
Aug 05, 2026, 4:48 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $6.67
Real-time Price: $6.50 info
Change: -$0.170 (-3%) info
Market Cap: $431.548M info